<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14376">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307294</url>
  </required_header>
  <id_info>
    <org_study_id>05-078</org_study_id>
    <nct_id>NCT00307294</nct_id>
  </id_info>
  <brief_title>Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)</brief_title>
  <official_title>Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate PSA response rates of the combination of
      Doxil and Thalidomide in patients with AIPC who have failed chemotherapy. Secondary
      objectives include: 1) To evaluate the clinical response rate of this combination on
      measurable disease 2) To evaluate overall survival for this combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, Phase II trial of thalidomide and Doxil in patients with androgen
      independent prostate cancer whom have a rising PSA while on chemotherapy. The primary
      objective of this study is to evaluate PSA response rates of the combination of Doxil and
      Thalidomide in patients with AIPC who have failed chemotherapy. Secondary objectives
      include: 1) To evaluate the clinical response rate of this combination on measurable disease
      (If measurable soft tissue lesions are present on radiological or clinical exam) ; 2) To
      evaluate overall survival for this combination. There will be between 18 and 35 subjects at
      least 18 years of age enrolled on this single site study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance/Safety</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>thalidomide and doxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Thalidomide and Doxil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg</description>
    <arm_group_label>thalidomide and doxil</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil</intervention_name>
    <description>On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days</description>
    <arm_group_label>thalidomide and doxil</arm_group_label>
    <other_name>doxorubicin liposome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.

          -  Confirmed androgen independent prostate cancer with evidence of rising PSA (two
             successive increases in PSA, at least 4 weeks apart) while on chemotherapy. If the
             PSA is less than 5, the increase in PSA must be at least 50%. Must also have castrate
             testosterone levels (&lt;50 ng/ml)

          -  Patients could not have received more than 2 previous chemotherapy regimens.

          -  No anthracyclines within the past 6 months.

          -  No prior single agent thalidomide in the last 12 months. No prior cytotoxic
             chemotherapy + thalidomide given in conjunction

          -  Age &gt; 18 years of age

          -  Performance status ECOG 0-2

          -  Peripheral neuropathy must be &lt; grade 1

          -  Must have adequate hematologic, hepatic and renal function

          -  Men of reproductive potential must be willing to consent to using effective
             contraception while on treatment and for at least 4 weeks thereafter

          -  Patients must have left ventricular ejection fraction of &gt; 50% within 42 days prior
             to first dose of study drug. The method used at baseline must be used for later
             monitoring

          -  Must have been off an anti-androgen for at least 4-6 weeks (Flutamide and
             Bicalutamide respectively) and documented as having a rising PSA

          -  Measurable or evaluable disease (PSA elevation will constitute evaluable disease).
             Measurable disease is defined as at least one lesion that can be accurately measured
             in at least one dimension (longest diameter to be recorded) as &gt;20 mm with
             conventional techniques CT scan or as &gt;10 mm with spiral CT scan. See section 6.B for
             the evaluation of measurable disease

          -  Life expectancy of greater than 3 months

          -  Patients must be willing and able to comply with the FDA-mandated S.T.E.P.S.® program

          -  Ability to understand and sign written informed consent approved by the Institutional
             Review Board [IRB/Ethics Committee], which will be obtained prior to study entry.

        Exclusion Criteria:

          -  Patients with unstable angina, uncompensated CHF, a history of an MI, PE or DVT
             within the last 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurkamal S Chatta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 14, 2016</lastchanged_date>
  <firstreceived_date>March 24, 2006</firstreceived_date>
  <firstreceived_results_date>January 14, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Androgen</keyword>
  <keyword>AIPC</keyword>
  <keyword>Doxil</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thalidomide and Doxil</title>
          <description>Combination of Thalidomide and Doxil
Thalidomide: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Doxil: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thalidomide and Doxil</title>
          <description>Combination of Thalidomide and Doxil
Thalidomide: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Doxil: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70" lower_limit="55" upper_limit="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide and Doxil</title>
            <description>Combination of Thalidomide and Doxil
Thalidomide: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Doxil: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Response Rate</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.3" lower_limit="2" upper_limit="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate</title>
        <time_frame>4 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>36 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance/Safety</title>
        <time_frame>4 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thalidomide and Doxil</title>
          <description>Combination of Thalidomide and Doxil
Thalidomide: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Doxil: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Watery eye (epiphora, tearing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Face</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Edema, larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils , Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Oral cavity-gums (gingivitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Sinus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy), Extraocular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy), Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mood alteration, Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU, Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urine color change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, Nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain, Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urticaria (hives, welts, wheals)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rita Johnson RN BSN CCRC</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-647-8571</phone>
      <email>johnsonr1@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
